Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [41] Cerebrospinal fluid markers for prediction of Alzheimer's disease
    Zetterberg, H
    Wahlund, LO
    Blennow, K
    NEUROSCIENCE LETTERS, 2003, 352 (01) : 67 - 69
  • [42] Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
    Czech, Christian
    Berndt, Peter
    Busch, Kristina
    Schmitz, Oliver
    Wiemer, Jan
    Most, Veronique
    Hampel, Harald
    Kastler, Juergen
    Senn, Hans
    PLOS ONE, 2012, 7 (02):
  • [43] Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer's disease
    Papassotiropoulos, A
    Maddalena, A
    Gretener, D
    Nitsch, RM
    Hock, C
    LIVING BRAIN AND ALZHEIMER'S DISEASE, 2004, : 17 - 24
  • [44] Microglial cerebrospinal fluid antibodies - Significance for Alzheimer disease
    McRae, A
    Ling, EA
    Wigander, A
    Dahlstrom, A
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1996, 28 (1-3) : 89 - 95
  • [45] Proteomic analysis of cerebrospinal fluid in Alzheimer's disease
    Watanabe, A
    Arai, H
    Asada, T
    Washimi, Y
    Endo, H
    Tabira, T
    NEUROBIOLOGY OF AGING, 2004, 25 : S359 - S359
  • [46] Plasma and Cerebrospinal Fluid Metals in Alzheimer's Disease
    Quinn, Joseph
    Anekonda, Thimmappa
    Kaye, Jeffrey
    Westaway, Shawn
    Harris, Christopher
    Robinson, Emily
    Ralle, Martina
    NEUROLOGY, 2011, 76 (09) : A229 - A229
  • [47] Cerebrospinal fluid and blood biomarkers in Alzheimer's disease
    Humpel, Christian
    Hochstrasser, Tanja
    WORLD JOURNAL OF PSYCHIATRY, 2011, 1 (01): : 8 - 18
  • [48] Cerebrospinal fluid production in Alzheimer's disease patients
    Religa, D.
    Andreasen, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 318 - 318
  • [49] Association of cerebrospinal fluid Neurogranin with Alzheimer's disease
    Wang, Lijun
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 31 (02) : 185 - 191
  • [50] CEREBROSPINAL-FLUID ACETYLCHOLINESTERASE IN ALZHEIMER-DISEASE
    FOLSTEIN, MF
    CLINICAL CHEMISTRY, 1984, 30 (06) : 1081 - 1082